CASE DISCUSSION
Use of Oral Glycemic Drugs in CKD
Presented from India by Dr. Adarsh K.S.Views
11,270
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
The use of oral glycemic drugs in patients with Chronic Kidney Disease (CKD) requires careful consideration due to altered drug metabolism and excretion associated with kidney dysfunction. Metformin, often the first-line treatment for type 2 diabetes, may be used with caution in mild to moderate...
Case Summary
- Chronic kidney disease (CKD) is defined by persistent kidney damage markers or an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m², persisting for at least three months. Diabetes is a leading cause of CKD, with 20-40% of diabetic patients developing CKD. Microvascular and macrovascular complications are often linked to diabetes, including diabetic nephropathy.
Speaker Profile
Dr. Adarsh K.S.
Consultant in Dept of Endocrinology, Manipal Hospitals,BangaloreDisclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.